23andMe Stock

23andme.com | Healthcare/Biotech | Founded: 2006 | Funding to Date: $791,607,056

23andMe was founded in April 2006 by Anne Wojcicki and Linda Avery. The company offers consumer genetic testing and supports genetic research. The consumer genetics and research platform give customers interactive, web-based access to their genetic profile. They regularly increase the capabilities of the platform giving users more insight into their DNA. In addition to ancestry insights, 23andMe provides users insights into their personal genetic health traits. The company has taken strategic steps to begin leveraging its genetic database to develop novel drugs, exemplified by the investment by and partnership with pharmaceutical company GSK in 2018. According to the company, 23andMe has millions of customers worldwide, and approximately 85% have consented to participate in research. 23andMe is located in Mountain View, CA. As of December 2019.

ENTERPRISE VALUE (based on primary fundings)

Key Investors
Fidelity Investments
Casdin Capital
Altimeter Capital
Sequoia Capital

Learn more about a potential 23andMe IPO >>

TEAM

Management Team
  • Anne Wojcicki - CEO & Co-Founder
  • Kathy Hibbs JD - Chief Legal & Regulatory Officer
  • Steve Schoch - CFO
  • Kenneth Hillan, M.B., Ch.B - Head of Therapeutics
  • Mike Polcari - Vice President & Chief Architect
  • Fred Kohler - Vice President, People
Board Members
  • Anne Wojcicki - 23andMe
  • Patrick Chung - Xfund
  • Neal Mohan - 23andMe
  • Roelof Botha - Sequoia Capital
  • Richard Scheller, Ph.D. - Self

NEWS

Recode

DNA tests were a big holiday hit — in 2018. This past year, Ancestry and 23andMe DNA kit sales on their websites saw major declines, according to new data. As a result, both 23andMe and Ancestry have recently had major layoffs.

Token Index
Private Growth Index
X